Stockscreener 앱 받기
9.21
1.92%
-0.18
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
BIOCRYST PHARMACEUTICALS Earnings Preview: Recent $BCRX Insider Trading, Hedge Fund Activity, and More - Nasdaq
BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
T-cell Lymphoma Market Generated Opportunities, Future Scope - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Savant Capital LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month HighStill a Buy? - MarketBeat
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.50 - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
JMP Securities maintains BioCryst stock with $18 target By Investing.com - Investing.com Canada
BioCryst up 8% after raising 2024 Orladeyo revenue guidance - MSN
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month HighTime to Buy? - MarketBeat
BioCryst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth - Simply Wall St
BioCryst stock soars to 52-week high, touches $9.02 By Investing.com - Investing.com South Africa
Oral HAE treatment Orladeyo now available to patients in Portugal - Angioedema News Today
Portugal approves daily oral therapy for hereditary angioedema By Investing.com - Investing.com Nigeria
Portugal approves daily oral therapy for hereditary angioedema - MSN
BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal - Marketscreener.com
BioCryst Launches ORLADEYO® (berotralstat) in Portugal - The Manila Times
Breakthrough: Portugal Gets First-Ever Daily Oral HAE Treatment as ORLADEYO Expands Global Reach - StockTitan
Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 - GlobeNewswire
Where are the Opportunities in (BCRX) - Stock Traders Daily
BioCryst to Present New ORLADEYO® (berotralstat) Results - GlobeNewswire
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress - The Manila Times
BCRX Unveils Groundbreaking Pediatric Trial Data: ORLADEYO Shows Promise in Children Under 12 - StockTitan
BioCryst (BCRX) Q4 Earnings Call: Key Financial Updates Coming February 24Here's What to Track - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month HighShould You Buy? - MarketBeat
BioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 9.1%Still a Buy? - MarketBeat
SG Americas Securities LLC Sells 117,571 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - Defense World
SG Americas Securities LLC Has $311,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Decrease in Short Interest - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inside BioCryst's Latest Executive Compensation Move: Key Details on New Hire Stock Grants - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Market Outperform" Rating at JMP Securities - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
0.27%
3.05%
자본화:
|
볼륨(24시간):